2,170 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Acquired by Wealthspire Advisors LLC

Wealthspire Advisors LLC purchased a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,170 shares of the company's stock, valued at approximately $402,000.

Several other hedge funds have also modified their holdings of INSP. Wasatch Advisors LP boosted its stake in Inspire Medical Systems by 1.6% in the third quarter. Wasatch Advisors LP now owns 1,323,470 shares of the company's stock valued at $279,318,000 after acquiring an additional 20,481 shares during the last quarter. State Street Corp boosted its stake in Inspire Medical Systems by 78.0% in the third quarter. State Street Corp now owns 1,049,784 shares of the company's stock valued at $221,557,000 after acquiring an additional 459,990 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Inspire Medical Systems by 5.8% in the third quarter. Janus Henderson Group PLC now owns 502,609 shares of the company's stock valued at $106,075,000 after acquiring an additional 27,374 shares during the last quarter. Geode Capital Management LLC boosted its stake in Inspire Medical Systems by 0.7% in the third quarter. Geode Capital Management LLC now owns 483,654 shares of the company's stock valued at $102,102,000 after acquiring an additional 3,128 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in Inspire Medical Systems in the fourth quarter valued at approximately $80,419,000. 94.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

INSP has been the topic of a number of recent research reports. KeyCorp reaffirmed an "overweight" rating and issued a $234.00 price objective (down from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Wells Fargo & Company reduced their price objective on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Truist Financial reduced their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a research report on Tuesday, February 11th. Bank of America raised shares of Inspire Medical Systems from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $220.00 to $255.00 in a research report on Wednesday, November 20th. Finally, Robert W. Baird reduced their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 11th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Inspire Medical Systems presently has an average rating of "Moderate Buy" and an average price target of $228.82.

Remove Ads

Inspire Medical Systems Stock Up 0.8 %

Shares of NYSE:INSP traded up $1.54 during midday trading on Friday, reaching $185.56. 414,828 shares of the company were exchanged, compared to its average volume of 607,237. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $257.40. The stock has a fifty day simple moving average of $187.87 and a two-hundred day simple moving average of $193.10. The firm has a market cap of $5.51 billion, a PE ratio of 107.26, a P/E/G ratio of 2.86 and a beta of 1.32.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. As a group, analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Insider Activity

In other news, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares of the company's stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares of the company's stock, valued at $1,332,026.50. The trade was a 77.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,225 shares of company stock valued at $4,806,530 in the last quarter. Company insiders own 4.10% of the company's stock.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.